|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
34
|
|
pubmed:dateCreated |
2009-11-26
|
|
pubmed:abstractText |
As a result of the questionable risk-to-benefit ratio of adjuvant therapies, stage II melanoma is currently managed by observation because available clinicopathologic parameters cannot identify the 20% to 60% of such patients likely to develop metastatic disease. Here, we propose a multimarker molecular prognostic assay that can help triage patients at increased risk of recurrence.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5772-80
|
|
pubmed:dateRevised |
2011-3-3
|
|
pubmed:meshHeading |
pubmed-meshheading:19884546-Activating Transcription Factor 2,
pubmed-meshheading:19884546-Algorithms,
pubmed-meshheading:19884546-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:19884546-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:19884546-Disease-Free Survival,
pubmed-meshheading:19884546-Female,
pubmed-meshheading:19884546-Humans,
pubmed-meshheading:19884546-Male,
pubmed-meshheading:19884546-Melanoma,
pubmed-meshheading:19884546-Middle Aged,
pubmed-meshheading:19884546-Prognosis,
pubmed-meshheading:19884546-Protein Array Analysis,
pubmed-meshheading:19884546-Skin Neoplasms,
pubmed-meshheading:19884546-Survival Rate,
pubmed-meshheading:19884546-Tissue Array Analysis,
pubmed-meshheading:19884546-Tumor Markers, Biological,
pubmed-meshheading:19884546-beta Catenin
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Melanoma prognostic model using tissue microarrays and genetic algorithms.
|
|
pubmed:affiliation |
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
